1 – 10 of 42
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Paquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouse
(
- Contribution to journal › Article
- 2016
-
Mark
CD14 is a co-receptor for TLR4 in the S100A9-induced pro-inflammatory response in monocytes
(
- Contribution to journal › Article
-
Mark
The anti-tumor effect of the quinoline-3-carboxamide tasquinimod : Blockade of recruitment of CD11b+ Ly6Chi cells to tumor tissue reduces tumor growth
(
- Contribution to journal › Article
- 2015
-
Mark
Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
(
- Contribution to journal › Article
-
Mark
Extracellular MRP8/14 is a regulator of β2 integrin-dependent neutrophil slow rolling and adhesion.
(
- Contribution to journal › Article
-
Mark
S100A9 as a pharmacological target molecule in inflammation and cancer.
(
- Contribution to journal › Article
- 2014
-
Mark
Quinoline-3-carboxamides modulate primary T cell-dependent B cell responses but do not inhibit functional immunity.
(
- Contribution to journal › Article
- 2013
-
Mark
Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment
(
- Contribution to journal › Article
-
Mark
Mice Lacking NCF1 Exhibit Reduced Growth of Implanted Melanoma and Carcinoma Tumors.
(
- Contribution to journal › Article
-
Mark
Common Interactions between S100A4 and S100A9 Defined by a Novel Chemical Probe.
(
- Contribution to journal › Article